Published in Vaccine Weekly, August 20th, 2003
The publication details results of a dose-ranging, placebo-controlled Phase I human trial and extension study of AVANT's cholesterol ester transfer protein (CETP) vaccine, CETi-1. This investigational vaccine is designed to elicit antibodies that bind and inhibit the activity of CETP, blocking the ability of that protein to transfer cholesterol from HDL to LDL and thus causing HDL cholesterol levels to rise.
A Phase II trial of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly